Pakistan’s drug regulator asks pharmacies to pull specific batches of Telosin and Bisgit after laboratory tests flagged an impurity failure and unexplained assay peaks.
ISLAMABAD, Nov. 16 (Focus Pakistan) - A new DRAP recall covers specific batches of two prescription medicines across the country after provincial drug testing laboratories in Punjab declared them substandard.
In a medical product alert issued on Monday, the regulator named Telosin SR 0.4mg capsules and Bisgit 5mg tablets, and directed manufacturers, distributors and pharmacies to withdraw the affected batches from circulation. According to DRAP, the substances found during testing could pose health risks as their effects are not known.
The alert does not report any confirmed harm to patients, nor does it say how many packs of the two batches have already reached pharmacies and hospitals.
Telosin SR 0.4mg contains tamsulosin hydrochloride and is used for urinary symptoms linked with an enlarged prostate. The Drug Testing Laboratory in Multan declared batch 57026 of the capsules, made by Briell Pharmaceuticals of Lahore, substandard on the basis of impurity testing.
Also Read: Medicines From Two Pakistani Pharma Companies Face Recall Over Excessive Impurities
Bisgit 5mg contains bisoprolol fumarate, a beta-blocker that doctors prescribe for heart conditions including high blood pressure and heart failure. The Drug Testing Laboratory in Rawalpindi found additional unexplained peaks in the assay test of batch T12426, made by Glitz Pharma of Islamabad. The alert does not say what those peaks represent.
The action covers only these two batches. It is not a ban on other batches sold under the same brand names.
What pharmacies must do
DRAP has told its field force and provincial drug control departments to survey markets and remove the affected stock. Manufacturers, importers and distributors must start the recall under the relevant rules.
Pharmacists and medical store owners must check their stock and stop selling the two batches at once. They should set aside any remaining packs and return them to the supplier or manufacturer.
The recall applies wherever the two batches may have gone in the supply chain, not only in Multan and Rawalpindi where the labs picked up the problems. DRAP has also called for closer surveillance across the distribution network.
Patients should check the batch number printed on the pack. Anyone holding Telosin batch 57026 should stop using it and ask a pharmacist or doctor for a replacement.
People taking Bisgit batch T12426 should not stop bisoprolol on their own. They should contact their doctor or pharmacist first to switch to an unaffected batch, because stopping a beta-blocker suddenly can cause problems of its own.
DRAP has asked consumers and health facilities to contact the supplier, distributor or manufacturer for returns, and wants healthcare professionals to report any suspected side effects or quality complaints to its National Pharmacovigilance Centre.
What the alert does not say
Impurity tests look for unwanted chemicals in a medicine, while an assay test checks its active content. Extra peaks in an assay can point to substances that need further investigation. DRAP’s alert, however, does not name any impurity, give levels or describe clinical effects, and it has not set a deadline for completing the recall or said how much stock has been recovered so far.






